Patents by Inventor Stephen A. Chappell
Stephen A. Chappell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7432346Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: GrantFiled: December 30, 2002Date of Patent: October 7, 2008Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
-
Publication number: 20070270580Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.Type: ApplicationFiled: November 29, 2006Publication date: November 22, 2007Inventors: Vincent Mauro, Gerald Edelman, Stephen Chappell, Frederick Jones, Geoffrey Owens, Robyn Meech
-
Patent number: 7183395Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating the oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.Type: GrantFiled: January 26, 2001Date of Patent: February 27, 2007Assignee: The Scripps Research InstituteInventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
-
Patent number: 7124376Abstract: A pre-designed system-on-chip architecture and method includes several standard library devices, HDL source code, simulation environment and regression, synthesis scripts, software header files, software libraries, ASIC verification test suites, and makefiles. The standard library devices comprise an integrated CPU, a shared memory controller, a peripheral controller, system peripherals, a DMA controller, embedded memory, and general system control. CPU bridges are used to accommodate a variety of processor types and to insulate users from the complexities of interfacing to different kinds of processors. Such CPU bridges further allow the latest processors to be rapidly integrated into existing integration platforms and designs.Type: GrantFiled: September 17, 2001Date of Patent: October 17, 2006Assignee: Palmchip CorporationInventors: S. Jauher A. Zaidi, Michael Ou, Lyle E. Adams, Stephen Chappell, Savitha Gandikota, Jon Udell, Brian Gutcher, Jef Munsil
-
Patent number: 7053186Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STREPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: December 6, 2001Date of Patent: May 30, 2006Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 6887975Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (serpentine transmembrane antigens of the prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: December 6, 2001Date of Patent: May 3, 2005Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 6833438Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: December 6, 1999Date of Patent: December 21, 2004Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20040219591Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAP's are described and characterized herein. The human STEAP's exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: ApplicationFiled: May 28, 2004Publication date: November 4, 2004Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20040219162Abstract: Described is a family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family is STEAP-1, which appears to be a type IIIa membrane protein. STEAP-1 is a 339 amino acid protein. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.Type: ApplicationFiled: May 28, 2004Publication date: November 4, 2004Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20040072196Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: ApplicationFiled: April 4, 2003Publication date: April 15, 2004Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20040043468Abstract: Synthetic and isolated translational regulatory elements, including oligonucleotides that have translational enhancing activity, internal ribosome entry site (IRES) activity, or translational inhibitory activity, and multimers of such translational regulatory elements are provided. In addition, compositions that include such translational regulatory elements are provided, as are methods of using the translational regulatory elements.Type: ApplicationFiled: November 27, 2002Publication date: March 4, 2004Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Geoffrey Owens, Jason K. Pinkstaff, Leslie Krushel, Wei Zhou
-
Publication number: 20040005564Abstract: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating the oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are vectors useful for identifying an oligonucleotide having transcriptional or translational regulatory activity according to a method of the invention. In addition, isolated synthetic transcriptional or translational regulatory elements identified according to a method of the invention are provided, as are kits, which contain a vector useful for identifying a transcriptional or translational regulatory element, or an isolated synthetic transcriptional or translational regulatory element or plurality of such elements. Also provided are isolated transcriptional regulatory elements.Type: ApplicationFiled: December 9, 2002Publication date: January 8, 2004Inventors: Vincent P. Mauro, Gerald M. Edelman, Stephen A. Chappell, Frederick S. Jones, Geoffrey Owens, Robyn Meech
-
Patent number: 6652859Abstract: Novel testis-specific genes and encoded proteins (PTANs) are described. PTANs are over-expressed in prostate cancer. The nucleotide and amino acid sequences of three distinct PTAN isoforms, designated PTAN-1, PTAN-2 and PTAN-3 are provided. The PTANs show no homology to any known gene. The testis-specific expression profile of PTAN in normal adult tissues, combined with the over-expression observed in prostate tumor xenografts, suggests that PTAN may be aberrancy over-expressed in at least some prostate cancers, and thus may be a useful diagnostic and/or therapeutic target for prostate cancers.Type: GrantFiled: September 30, 1999Date of Patent: November 25, 2003Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Arthur B. Raitano, Stephen Chappell Mitchell
-
Publication number: 20030211520Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: ApplicationFiled: December 30, 2002Publication date: November 13, 2003Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
-
Publication number: 20030055217Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds In a “serpentine” manner into three extracellular and two intracellular loops.Type: ApplicationFiled: December 6, 2001Publication date: March 20, 2003Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Publication number: 20030045682Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: ApplicationFiled: December 6, 2001Publication date: March 6, 2003Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell
-
Patent number: 6509458Abstract: A novel testis-specific gene expressed in human prostate cancer, designated 22P4F11, is described. Analysis of 22P4F11 mRNA expression in normal prostate, prostate tumor xenografts, and a variety of normal tissues indicates that the expression of this gene is testis specific in normal tissues. The 22P4F11 gene is also expressed in human prostate tumors, in some cases at high levels. A full length cDNA encoding 22P4F11 is provided. The 22P4F11 transcript and/or protein may represent a useful diagnostic marker and/or therapeutic target for prostate cancer.Type: GrantFiled: September 30, 1999Date of Patent: January 21, 2003Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Stephen Chappell Mitchell
-
Publication number: 20020038401Abstract: A pre-designed system-on-chip architecture and method includes several standard library devices, HDL source code, simulation environment and regression, synthesis scripts, software header files, software libraries, ASIC verification test suites, and makefiles. The standard library devices comprise an integrated CPU, a shared memory controller, a peripheral controller, system peripherals, a DMA controller, embedded memory, and general system control. CPU bridges are used to accommodate a variety of processor types and to insulate users from the complexities of interfacing to different kinds of processors. Such CPU bridges further allow the latest processors to be rapidly integrated into existing integration platforms and designs.Type: ApplicationFiled: September 17, 2001Publication date: March 28, 2002Inventors: S. Jauher A. Zaidi, Michael Ou, Lyle E. Adams, Stephen Chappell, Savitha Gandikota, Jon Udell, Brian Gutcher, Jef Munsil
-
Patent number: 6329503Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: June 1, 1999Date of Patent: December 11, 2001Assignee: Agensys, Inc.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran, Stephen Chappell Mitchell